Reference(s) to `NCCc1ccc(O)c(O)c1' in wdi981demo:

Indications and usage

Myocardial-infarction; trauma; endotoxic sepsis; open-heart-surgery;low cardiac-output; cardiac-failure; chronic cardiac-decompensation;impending renal-failure.

Precautions and warnings

Pregnancy; children; peripheral vascular-disease; avoid extravasation; cyclopropane; halogenated hydrocarbon anesthetics; begin treatment with one-tenth of the usual dose in those who have been treated with MAO-inhibitors; correct hypovolemia if necessary prior to treatment; inject into a large vein if possible; safety and efficacy in children have not been established; use glucose solutions with care in diabetics; monitor with history of peripheral vascular-disease for signs of compromized circulation to the extremities; glucose solutions without electrolytes should not be administered simultaneously with blood through the same infusion set; decrease infusion-rate in event of a disproportionate increase in diastolic pressure and observe for further evidence of predominant vasoconstriction unless this is desired.


Pheochromocytoma; uncorrected tachyarrhythmia; uncorrected ventricularfibrillation.


Cyclopropane; MAO-inhibitors; potassium-free solutions; halogenatedhydrocarbon anesthetics.

Adverse effects

Ectopic-beats; tachycardia; arrhythmia; cardiopathy; angina-pectoris;palpitations; dyspnea; nausea; coronary-disease; GI-disorder; vomiting;hypotension; vasoconstriction; cardiac-conduction-disorder; hypertension;vascular-disease; bradycardia; piloerection; widened QRS-complex; azotemia.

Mechanism of action

DOPAMINERGIC; PROLACTIN-ANTAGONIST; SYMPATHOMIMETIC-ALPHA;SYMPATHOMIMETIC-BETA; VASODILATOR; HYPERTENSIVE; noradrenaline precursor;releases noradrenaline stores natriuretic; acts directly and indirectly onalpha adrenergic-receptors and beta-1 adrenergic-receptors; increases systolicB.P.; increases pulse-pressure peripheral blood-flow may decrease; mesentericblood-flow may increase; produces renal vasodilatation; produces mesentericvasodilatation; increases glomerular filtration rate; inotropic effect on themyocardium resulting in increased cardiac-output; increased urinary output isnot associated with decreased urinary osmolality.

Trade name

Daylight Chemical Information Systems Inc.